David Gustafsson
AstraZeneca R&D
Mölndal
Sweden
Name/email consistency: high
- A new oral anticoagulant: the 50-year challenge. Gustafsson, D., Bylund, R., Antonsson, T., Nilsson, I., Nyström, J.E., Eriksson, U., Bredberg, U., Teger-Nilsson, A.C. Nat. Rev. Drug. Discov (2004)
- The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. Gustafsson, D., Elg, M. Thromb. Res. (2003)
- Oral direct thrombin inhibitors in clinical development. Gustafsson, D. J. Intern. Med. (2003)
- The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Gustafsson, D., Nyström, J., Carlsson, S., Bredberg, U., Eriksson, U., Gyzander, E., Elg, M., Antonsson, T., Hoffmann, K., Ungell, A., Sörensen, H., Någård, S., Abrahamsson, A., Bylund, R. Thromb. Res. (2001)